ARA-290

Dr. Jones notes that peptides are commonly associated with muscle building and fat loss, but argues they are highly effective for nerve pain — a use case he considers underappreciated by the general public. This framing serves as context for the broader discussion of BPC-157, Thymosin Beta-4, and ARA-290 in neuropathic conditions. No dosages are mentioned.

Dr. Jones strongly emphasizes ARA-290 as his top recommendation specifically for small fiber neuropathies and autonomic dysfunction, calling it 'the small nerve fiber peptide.' He presents this with notable conviction, suggesting it is a highly targeted and effective option for these specific conditions. No dosage or protocol details are provided in this excerpt.

The clinician offers a broad expert opinion that peptides as a class demonstrate powerful nerve-treating and neuroprotective abilities, though he acknowledges they do not help every condition. This claim is based on his clinical experience rather than cited studies. No specific mechanism of action is elaborated upon in this excerpt.

The case highlights intramuscular (IM) injection as a practical alternative administration route when intravenous (IV) access is difficult or not feasible. Both ARA-290 and Cerebrolysin were administered intramuscularly in this instance. No dosage, volume, or injection site details were provided.

A college student presenting with involuntary arm movements received intramuscular injections of both ARA-290 and Cerebrolysin. According to the clinician's account, her symptoms resolved rapidly — within the time it took the doctor to see another patient and return. No specific dosages were mentioned for either compound.